Navigation Links
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
Date:4/15/2008

spray, two sprays in each nostril, after which they self-reported their allergy symptoms hourly for the subsequent 12 hours. PATANASE(R) nasal spray was found to have an onset of action of 30 minutes and a 12 hour duration of affect after dosing, which was statistically significant compared to the placebo spray.

"For patients who suffer every allergy season with symptoms that make life in those months miserable, PATANASE(R) offers relief beginning in minutes in a convenient steroid-free nasal spray," said Eli Meltzer, M.D., Medical Group and Research Center, A.P.C., San Diego, CA, and lead investigator on one study submitted to the FDA. "The fact that it works quickly is important. Patients in our fast paced society want rapid improvement and relief from their nasal allergies."

About PATANASE(R) Nasal Spray

PATANASE(R) nasal spray is indicated for patients 12 years of age and older for the relief of symptoms of seasonal allergic rhinitis. Nasal allergy symptoms are measured by the patient's Total Nasal Symptom Score (TNSS) which is a combination of stuffy, runny, itchy nose and sneezing. PATANASE(R) is intended only for intranasal administration. The most common side effects experienced with the use of PATANASE(R) include: bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and urinary tract infection.

About Seasonal Allergic Rhinitis

Seasonal allergic rhinitis, also known as "hay fever," refers to an allergic complex of symptoms caused by sensitivity to seasonal pollens. Symptoms may include congestion, sneezing, itchy nose, runny nose, watery eyes and itchy eyes.

According to the American College of Allergy, Asthma & Immunology (ACAAI), allergies affect an estimated 40 to 50 million people in the United States. Allergies are not only bothersome, but have been linked to a variety of common and serious chronic respiratory illnesses, such as sinusitis and asthma. In addition, they may interfere
'/>"/>

SOURCE Alcon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
2. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
3. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
4. Researchers Pursuing Nasal Anthrax Vaccine
5. Nasal polyps from analgesics
6. Saline Nasal Wash Helps Kids Fight Colds, Flu
7. Protein Nasal Spray Revives Sleep-Deprived Monkeys
8. Saline Irrigation Eases Chronic Nasal Symptoms
9. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
10. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
11. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 2Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 3Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 4Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 5Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 6Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 7Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3
Breaking Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Ascension Orthopedics Hires Key Senior Executives 2Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 1Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 2Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 3Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 4Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 5Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 6Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 7Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 8Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 9Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 10Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 11Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 12Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 13ETC Biomedical Announces Chamber Sale in India 13344 1ETC Biomedical Announces Chamber Sale in India 13344 2ETC Biomedical Announces Chamber Sale in India 13344 3ETC Biomedical Announces Chamber Sale in India 13344 4OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 1OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 3